NCT04758078

Inhaled Budesonide in Transient Tachypnea of the Newborn

Inhaled Budesonide in Transient Tachypnea of the Newborn: A Randomized, Placebo-controlled Study

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Makassed General Hospital · Academic / Other
• Sex: All
• Age: 34 Weeks
• Healthy volunteers: Not accepted

Summary

Background: Transient tachypnea of the newborn (TTN) caused by lung edema resulting from delayed absorption of fetal alveolar lung fluid and is a common cause of admission of late preterm and full-term infants to neonatal intensive care units. Infant born by C-section and those with perinatal asphyxia, umbilical cord prolapse or certain maternal condition (asthma, diabetes, or analgesia) are more prone to develop TTN. Conventional treatment involves appropriate oxygen administration and continuous positive airway pressure in some cases. Hastening the clearance of lung liquid should shorten the duration of the symptoms and reduce complications. Objectives: This study aims to determine the effectiveness of inhaled budesonide in the treatment of this disorder through determining whether it reduces the duration of oxygen therapy and respiratory symptoms and shortens hospital stay in term infants with transient tachypnea of the newborn

Conditions

• Respiratory Distress

Interventions

Type	Name	Description
OTHER	Inhaled corticosteroids	Budesonide 2 mL = 1000 microgram will be given within 6 hours of birth and the second dose will be given after 12 hours
OTHER	Placebo	Nebulized 0.9% saline will be given four times per day

Timeline

• Start date: 2021-02-15
• Primary completion: 2021-08-01
• Completion: 2021-08-01
• First posted: 2021-02-17
• Last updated: 2021-03-03

Locations

1 site across 1 country: Lebanon